An international research team led by the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects. Their new material could be developed into an antimicrobial drug to treat patients with antibioticresistant infections.
This finding was reported in the scientific journal Nature Communications.
Superbugs that are resistant to antibiotics are a serious health threat. According to the UK Review on Antimicrobial Resistance, superbugs kill around 700,000 people worldwide each year. By 2050, 10 million people could die each year if existing antibiotics continue to lose their effectiveness.
“There is an urgent global need for new antimicrobials that are effective against superbugs. The situation has become more acute because bacteria are starting to develop resistance to the last-line antibiotics, which are given only to patients infected with bacteria resistant to available antibiotics,” said Professor Jackie Y. Ying, Executive Director of IBN.
The research community is trying to develop alternatives to antibiotics using synthetic polymers. However, the antimicrobial polymers developed so far are either too toxic for clinical use, not biodegradable or can only target one type of bacteria.
To address this problem, Dr Yi Yan Yang from IBN brought together a multidisciplinary research team from the US, China and Singapore to develop a new class of antimicrobial polymers called guanidinium-functionalized polycarbonates with a unique killing mechanism that can target a broad range of multidrug-resistant bacteria. It is biodegradable and non-toxic to human cells.
The polymer kills bacteria in the following way. First, the polymer binds specifically to the bacterial cell. Then, the polymer is transported across the bacterial cell membrane into the cytoplasm, where it causes precipitation of the cell contents (proteins and genes), resulting in cell death.
The team tested the polymers on mice infected with five hard-to-treat multidrug-resistant bacteria: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, methicillinresistant Staphylococcus aureu and Pseudomonas aeruginosa. These superbugs are commonly acquired by patients in the hospitals and can cause systemic infections that lead to septic shock and multiple organ failure. The results showed that the bacteria were effectively removed from the mice and no toxicity was observed.
The researchers then further tested the effectiveness of the polymers on mice with two types of systemic infections caused by superbugs: peritonitis (an infection of the stomach’s inner lining) and lung infections from Pseudomonas aeruginosa. The polymers eliminated the bacterial infections in both groups of mice with negligible toxicity.
Dr Yi Yan Yang, Group Leader at IBN said, “We have demonstrated the first example of a biodegradable synthetic macromolecule with broad-spectrum antimicrobial activity in mice, unique killing mechanism and no toxicity. Once the polymer finishes its job of killing the bacteria, it will be naturally degraded after three days and will not remain in the body. This antimicrobial agent shows great promise for the treatment and prevention of multidrug-resistant systemic infections.”
“This study illustrates the potential for this new research field we denote as ‘macromolecular therapeutics’ to create entirely new classes of treatments for multiple diseases,” said Dr James Hedrick, Distinguished Research Staff Member, IBM Research – Almaden, San Jose, California. “In 2016, we demonstrated the efficacy of synthetic polymers to combat deadly viral diseases. The current research for treating bacterial infections rounds out our ability to someday treat a spectrum of infectious diseases with a single, new type of mechanism without the onset of resistance.”
To determine whether the bacteria will develop any resistance to the polymer, the team collaborated with Dr Paola Florez de Sessions at A*STAR’s Genome Institute of Singapore and the Cell Engineering group of Dr Simone Bianco at IBM Research – Almaden to perform genomic analysis. They found that the bacteria did not show any resistance development even after multiple treatments with the polymer.
The Latest on: Antimicrobial drug
via Google News
The Latest on: Antimicrobial drug
- Slimy but useful: Snail mucus found to have uses in development of anti-cancer drugs, water purificationon October 20, 2021 at 8:01 am
Snail mucus, secretions of snails which are normally considered as agricultural pests, has several applications in the development of anticancer and antimicrobial drugs as well as biosensors for the ...
- Entasis' (ETTX) Phase III Study on Infection Drug Meets Goalon October 20, 2021 at 7:36 am
Entasis ETTX announced positive top-line data from the phase III ATTACK study evaluating its investigational intravenous (IV) drug, sulbactam-durlobactam (“SUL-DUR”), in patients having infections ...
- Entasis antibiotic bests last-resort drug in Phase 3 trial; FDA filing planned for 2022on October 19, 2021 at 1:28 pm
Entasis Therapeutics, the former anti-infectives unit of AstraZeneca, has positive Phase 3 data for its lead program, an antibiotic that could address drug-resistant strains of Acinetobacter baumannii ...
- Antibiotic Prescribing and Stewardship During COVID-19on October 19, 2021 at 8:08 am
Stewardship programs are critical for optimizing patient safety, and there are opportunities to optimize antibiotic use during the COVID-19 pandemic.
- Entasis' antibiotic bests last resort treatment on path to become new weapon against drug-resistant bacteriaon October 19, 2021 at 7:35 am
A new antibiotic by Entasis Therapeutics has bested an existing therapy against a pathogen deemed by the CDC to be an urgent threat during a phase 3 clinical trial.
- Killing bacteria with viruses: The answer to antibiotic resistance?on October 19, 2021 at 5:55 am
A recent study brings us a few steps closer to treating certain bacterial infections with bacteria-killing viruses called bacteriophages.
- CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infectionson October 18, 2021 at 6:00 pm
Debiopharm ( a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the ...
- Influence of Humans on Evolution and Mobilization of Environmental Antibiotic Resistomeon October 14, 2021 at 6:58 pm
The clinical failure of antimicrobial drugs that were previously effective in controlling infectious disease is a tragedy of increasing magnitude that gravely affects human health. This resistance by ...
- Gel fights drug-resistant bacteria and induces body's natural immune defenseon October 14, 2021 at 7:52 am
In the fight against multidrug-resistant bacteria, scientists in Sweden have developed a new kind of antibiotic-free protection for wounds that kills drug-resistant bacteria and induces the body's own ...
- Antibiotic Resistance Market Sales Revenue to Significantly Increase in the Next Few Yearson October 11, 2021 at 11:47 pm
The Antibiotic Resistance Market is expected to be worth US 12 6 Bn at a CAGR of 4 between 2021 to 2031 Healthcare is going the digital way In other words artificial intelligence AI enabled medical ...
via Bing News